** Shares in Orion ORNBV.HE fall around 8% to their lowest price since July after the Finnish drugmaker posted Q3 sales miss and narrowed its 2025 guidance
** Jefferies says the sales, at EUR 423.2 million ($493.54 million), came in 1% below consensus due to weaker performance in Branded Products and Animal Health
** The brokerage also points out that the narrowed guidance came as a surprise as investors had expected an upgrade
** The stock is at the bottom of STOXX 600 .STOXX index
($1 = 0.8575 euros)
(Reporting by Agnieszka Gosciak-Rabalska)
((agnieszka.gosciakgdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))